Skip to content

Intercept Pharmaceuticals, Inc.: 10-K filed 2013-04-01

What Intercept Pharmaceuticals, Inc. reported in its annual report filed 2013-04-01 (fiscal FY 2012): 27 published measures, 131 facts as tagged in accession 0001144204-13-019166.

This filing

Form
10-K (annual report)
Filed
2013-04-01
Fiscal period
fiscal FY 2012
Accession
0001144204-13-019166 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Intercept Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-12-31112,178,597USD
At 2011-12-3119,470,329USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-12-3146,266,732USD
At 2011-12-3122,030,107USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-12-3165,911,865USD
At 2011-12-31-2,559,778USD
At 2010-12-318,318,466USD
At 2009-12-312,122,760USD
At 2008-12-3117,685,476USD
At 2007-12-316,485,821USD
At 2002-09-030USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-12-3145,511,641USD
At 2011-12-3117,707,476USD
At 2010-12-3115,423,746USD
At 2009-12-314,434,719USD
At 2002-09-030USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-10-01 to 2012-12-31-30,690,403USD92
2012-01-01 to 2012-12-31-43,643,071USD366
2002-09-04 to 2012-12-31-118,183,350USD3772
2012-07-01 to 2012-09-30-5,186,988USD92
2012-04-01 to 2012-06-30-5,085,988USD91
2012-01-01 to 2012-03-31-2,679,692USD91
2011-10-01 to 2011-12-31-3,645,808USD92
2011-01-01 to 2011-12-31-12,737,654USD365
2011-07-01 to 2011-09-30-2,840,930USD92
2011-04-01 to 2011-06-30-2,918,006USD91
2011-01-01 to 2011-03-31-3,332,910USD90
2010-01-01 to 2010-12-31-15,087,223USD365
2009-01-01 to 2009-12-31-14,354,522USD365
2008-01-01 to 2008-12-31-13,704,870USD366
2002-09-04 to 2007-12-31-18,656,010USD1945

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-15,749,468USD366
2002-09-04 to 2012-12-31-67,645,053USD3772
2011-01-01 to 2011-12-312,605,786USD365
2010-01-01 to 2010-12-31-13,657,823USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2012-01-01 to 2012-12-3138,795USD366
2002-09-04 to 2012-12-311,397,238USD3772
2011-01-01 to 2011-12-3162,817USD365
2010-01-01 to 2010-12-3129,063USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-12-31108,418,234USD366
2002-09-04 to 2012-12-31180,195,197USD3772
2011-01-01 to 2011-12-31-249,667USD365
2010-01-01 to 2010-12-3124,618,090USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-64,857,368USD366
2002-09-04 to 2012-12-31-66,846,770USD3772
2011-01-01 to 2011-12-31-66,044USD365
2010-01-01 to 2010-12-3157,859USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-12-31148,838USD
At 2011-12-31311,366USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-01-01 to 2012-12-313,348,989USD366
2002-09-04 to 2012-12-319,777,870USD3772
2011-01-01 to 2011-12-311,865,755USD365
2010-01-01 to 2010-12-311,692,885USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-12-31111,778,219USD
At 2011-12-3118,904,094USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-12-3112,964,054USD
At 2011-12-314,032,067USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-12-311,180,000USD
At 2011-12-31604,000USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-10-01 to 2012-12-314,786,640USD92
2012-01-01 to 2012-12-3116,182,564USD366
2002-09-04 to 2012-12-3171,434,691USD3772
2012-07-01 to 2012-09-303,318,310USD92
2012-04-01 to 2012-06-305,018,029USD91
2012-01-01 to 2012-03-313,059,585USD91
2011-10-01 to 2011-12-314,163,094USD92
2011-01-01 to 2011-12-3111,426,155USD365
2011-07-01 to 2011-09-302,512,248USD92
2011-04-01 to 2011-06-302,521,268USD91
2011-01-01 to 2011-03-312,229,545USD90
2010-01-01 to 2010-12-3112,709,590USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-12-3116,526,885shares
At 2011-12-313,329,666shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-12-31184,100,139USD
At 2011-12-3172,133,893USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2012-12-31-21,451USD
At 2011-12-31-184,500USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2012-12-31813,000USD
At 2011-12-311,819,000USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2012-12-31664,000USD
At 2011-12-311,508,000USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2012-12-311,584,308USD
At 2011-12-311,196,618USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2012-12-3137,900,000USD
At 2011-12-3132,100,000USD
At 2010-12-3126,600,000USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2012-10-01 to 2012-12-31-30,820,838USD92
2012-01-01 to 2012-12-31-46,273,506USD366
2002-09-04 to 2012-12-31-129,127,484USD3772
2012-07-01 to 2012-09-30-6,186,988USD92
2012-04-01 to 2012-06-30-5,835,988USD91
2012-01-01 to 2012-03-31-3,429,692USD91
2011-10-01 to 2011-12-31-4,395,808USD92
2011-01-01 to 2011-12-31-15,737,654USD365
2011-07-01 to 2011-09-30-3,590,930USD92
2011-04-01 to 2011-06-30-3,668,006USD91
2011-01-01 to 2011-03-31-4,082,910USD90
2010-01-01 to 2010-12-31-17,988,593USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-10-01 to 2012-12-312,183,008USD92
2012-01-01 to 2012-12-315,177,129USD366
2002-09-04 to 2012-12-3129,598,082USD3772
2012-07-01 to 2012-09-30991,062USD92
2012-04-01 to 2012-06-30943,857USD91
2012-01-01 to 2012-03-311,059,202USD91
2011-10-01 to 2011-12-311,035,343USD92
2011-01-01 to 2011-12-314,209,429USD365
2011-07-01 to 2011-09-301,154,090USD92
2011-04-01 to 2011-06-30894,248USD91
2011-01-01 to 2011-03-311,125,748USD90
2010-01-01 to 2010-12-313,643,623USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2012-01-01 to 2012-12-31201,323USD366
2002-09-04 to 2012-12-312,366,669USD3772
2011-01-01 to 2011-12-31410,601USD365
2010-01-01 to 2010-12-31479,500USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2012-10-01 to 2012-12-31-24,126,160USD92
2012-01-01 to 2012-12-31-24,729,483USD366
2002-09-04 to 2012-12-31-21,401,812USD3772
2012-07-01 to 2012-09-30-1,400,807USD92
2012-04-01 to 2012-06-30117,143USD91
2012-01-01 to 2012-03-31680,341USD91
2011-10-01 to 2011-12-31793,876USD92
2011-01-01 to 2011-12-311,092,800USD365
2011-07-01 to 2011-09-30184,436USD92
2011-04-01 to 2011-06-3092,105USD91
2011-01-01 to 2011-03-3122,383USD90
2010-01-01 to 2010-12-311,265,990USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-01-01 to 2012-12-31108,499,996USD366
2002-09-04 to 2012-12-31172,477,162USD3772
2012-10-01 to 2012-10-3178,700,000USD31
2011-01-01 to 2011-12-310USD365
2010-01-01 to 2010-12-3119,690,079USD365

Inspect the source

Entity
Intercept Pharmaceuticals, Inc. / CIK 0001270073
Captured
SEC response SHA-256
189a532afeabeae693af9861cccd21096e4f8b32f84ccd47de7c30ab97054fba

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001270073.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))